Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful…